MedTrace Logo

Use of NovoSeven® in Active Variceal Bleeding

NCT00154492 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 265

Last updated 2017-01-13

No results posted yet for this study

Summary

This trial is conducted in Asia and Europe. The trial is planned to investigate the effectiveness and safety of NovoSeven® in patients with advanced cirrhosis and active variceal bleeding.

Conditions

  • Acquired Bleeding Disorder
  • Cirrhosis

Interventions

DRUG

activated recombinant human factor VII

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2006-08-31
Completion
2006-08-31

Countries

  • Austria
  • Czechia
  • Denmark
  • Finland
  • France
  • Germany
  • Hong Kong
  • Italy
  • Poland
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00154492 on ClinicalTrials.gov